CA2931064C - Withanolides useful for the treatment of neurodegenerative diseases - Google Patents

Withanolides useful for the treatment of neurodegenerative diseases Download PDF

Info

Publication number
CA2931064C
CA2931064C CA2931064A CA2931064A CA2931064C CA 2931064 C CA2931064 C CA 2931064C CA 2931064 A CA2931064 A CA 2931064A CA 2931064 A CA2931064 A CA 2931064A CA 2931064 C CA2931064 C CA 2931064C
Authority
CA
Canada
Prior art keywords
compound
patient
preventing
treating
need
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2931064A
Other languages
English (en)
French (fr)
Other versions
CA2931064A1 (en
Inventor
Agnes H. Chan
Jean-Pierre Julien
Anthony A. Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Université Laval
Arna Therapeutics Inc
Original Assignee
Université Laval
Imstar Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université Laval, Imstar Therapeutics Inc filed Critical Université Laval
Publication of CA2931064A1 publication Critical patent/CA2931064A1/en
Application granted granted Critical
Publication of CA2931064C publication Critical patent/CA2931064C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2931064A 2013-11-25 2014-11-25 Withanolides useful for the treatment of neurodegenerative diseases Active CA2931064C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361908455P 2013-11-25 2013-11-25
US61/908,455 2013-11-25
PCT/US2014/067436 WO2015077780A1 (en) 2013-11-25 2014-11-25 Withanolides useful for the treatment of neurodegenerative diseases

Publications (2)

Publication Number Publication Date
CA2931064A1 CA2931064A1 (en) 2015-05-28
CA2931064C true CA2931064C (en) 2022-10-18

Family

ID=52023694

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2931064A Active CA2931064C (en) 2013-11-25 2014-11-25 Withanolides useful for the treatment of neurodegenerative diseases

Country Status (14)

Country Link
US (1) US10351590B2 (enExample)
EP (1) EP3074414B1 (enExample)
JP (1) JP6517833B2 (enExample)
KR (1) KR20160137945A (enExample)
CN (1) CN105940010B (enExample)
AU (1) AU2014352629B2 (enExample)
BR (1) BR112016012002A2 (enExample)
CA (1) CA2931064C (enExample)
ES (1) ES2728870T3 (enExample)
MX (1) MX364528B (enExample)
PL (1) PL3074414T3 (enExample)
TR (1) TR201905218T4 (enExample)
WO (1) WO2015077780A1 (enExample)
ZA (1) ZA201603117B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019116069A1 (en) * 2017-12-11 2019-06-20 Ethnodyne Compounds for treating neurodegenerative disorders
US20210087222A1 (en) * 2017-12-11 2021-03-25 Ethnodyne Compounds for treating neurodegenerative disorders
EP3724207A1 (en) * 2017-12-11 2020-10-21 Ethnodyne Compounds for treating neurodegenerative disorders
CN111377994A (zh) * 2018-12-28 2020-07-07 南开大学 七种来源于灯笼果的醉茄内酯类化合物及其制备方法和用途
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
CN116063373B (zh) * 2023-02-14 2025-04-15 广西医科大学 天然产物27-Deoxywithaferin A的制备方法
EP4788688A1 (en) * 2023-10-03 2026-08-12 Enveda Therapeutics, Inc. Withaferin a analog and method for treatment using the same
CN117924401B (zh) * 2024-01-22 2026-05-12 黑龙江中医药大学 一种具有神经炎症抑制活性的化合物及其提取方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010030395A2 (en) * 2008-09-15 2010-03-18 Whitehead Institute For Biomedical Research Withaferin a analogs and uses thereof
WO2010053655A2 (en) 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
US8598339B2 (en) 2011-02-01 2013-12-03 University Of Kansas Withanolide isolated from Physalis longifolia and analogs and methods of use thereof
ES2679289T3 (es) * 2011-06-22 2018-08-23 UNIVERSITé LAVAL Procedimientos para el pronóstico y/o diagnóstico de una enfermedad neurodegenerativa, procedimientos para identificar compuestos candidatos y compuestos para tratar una enfermedad neurodegenerativa

Also Published As

Publication number Publication date
KR20160137945A (ko) 2016-12-02
EP3074414A1 (en) 2016-10-05
WO2015077780A1 (en) 2015-05-28
MX364528B (es) 2019-04-30
AU2014352629B2 (en) 2019-03-28
JP6517833B2 (ja) 2019-05-22
JP2016537432A (ja) 2016-12-01
MX2016006544A (es) 2016-12-12
CN105940010B (zh) 2018-03-30
PL3074414T3 (pl) 2019-12-31
US10351590B2 (en) 2019-07-16
CN105940010A (zh) 2016-09-14
CA2931064A1 (en) 2015-05-28
EP3074414B1 (en) 2019-01-09
BR112016012002A2 (pt) 2017-09-19
US20170022247A1 (en) 2017-01-26
ES2728870T3 (es) 2019-10-29
ZA201603117B (en) 2020-05-27
AU2014352629A1 (en) 2016-05-26
TR201905218T4 (tr) 2019-05-21

Similar Documents

Publication Publication Date Title
AU2014352629B2 (en) Withanolides useful for the treatment of neurodegenerative diseases
CN106103452B (zh) 皮质抑素类似物及其合成和用途
US20240254095A1 (en) NMDA Receptor Antagonist and Use Thereof
US12060379B2 (en) Plasmalogen derivatives
US10857163B1 (en) Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US11046684B2 (en) Compound for selectively inhibiting kinase and use thereof
IL291835A (en) Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof
US11472832B2 (en) Withanolides useful for the treatment of neurodegenerative diseases
RU2672569C2 (ru) Новое производное оксима хромона и его использование в качестве аллостерического модулятора метаботропных рецепторов глутамата
JP7295145B2 (ja) 神経変性疾患を治療するための医薬及びその使用
US8809395B2 (en) Methods for making valerenic acid derivatives and their use
JP7382944B2 (ja) 神経変性疾患を予防・治療するための新規な化合物及びその応用
CN118510544A (zh) 大麻素类的磷酸酯前药
JP2024534558A (ja) 重水素化ｎｍｄａ正調節化合物及びその使用方法
KR20250142441A (ko) 신규 키나제 억제제
CN120289443A (zh) 一种白杨素和硫辛酸拼接物及其制备方法和应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191121

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260109

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260313

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260313

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260420

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260619

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260801